Literature DB >> 27231860

What We Know About the Pathogenesis of Idiopathic Pulmonary Fibrosis.

S Puglisi1, S E Torrisi1, R Giuliano1, V Vindigni1, C Vancheri1.   

Abstract

Idiopathic pulmonary fibrosis (IPF) is a chronic progressive lung disease of unknown cause, occurring in adults, limited to the lungs and associated with the pathologic and radiologic pattern of usual interstitial pneumonia. Prognosis is poor, and most patients die of respiratory failure within 3 to 6 years from the onset of symptoms. Although our understanding of the pathogenesis of IPF has improved over the past two decades, the mechanisms responsible for this disorder have not been clearly defined. Aging is the single most important risk factor, but genetic, environmental, and diverse exogenous factors such as smoking, viral infections, chronic tissue injury (i.e., gastroesophageal reflux disease, traction injury) play contributory roles. In this review, we focus on pathogenetic mechanisms that we think are crucial for the initiation of the fibrotic process and for its progressive evolution. In the early stage of the disease, in the context of the permissive genetic background combined with the presence of specific risk factors, alveolar epithelial cells play a leading role. Subsequent evolution of the fibrotic process and its lethal progression is likely due to the abnormal tissue repair process that takes place in the lung and to the inability to counteract this process. In this phase of the disease, fibroblasts assume a crucial role. Current pharmacological treatment strategies for IPF have only modest value, principally by slowing the course of disease progression. Unfortunately, improvement or cure has not yet been achieved with pharmacological agents. The challenge for the future is to improve the comprehension of the mechanisms involved in the inception and evolution of IPF and their articulated interactions. This is fundamental not only to conceive and develop new drugs against this dreadful disease but also to apply different therapeutic approaches such as drug repositioning and personalized therapies in the management of IPF. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Year:  2016        PMID: 27231860     DOI: 10.1055/s-0036-1580693

Source DB:  PubMed          Journal:  Semin Respir Crit Care Med        ISSN: 1069-3424            Impact factor:   3.119


  14 in total

1.  Antiinflammation and Antioxidant Effects of Thalidomide on Pulmonary Fibrosis in Mice and Human Lung Fibroblasts.

Authors:  Xiaoying Dong; Xin Li; Minghui Li; Ming Chen; Qian Fan; Wei Wei
Journal:  Inflammation       Date:  2017-12       Impact factor: 4.092

Review 2.  Imaging Pulmonary Inflammation.

Authors:  Philip M Scherer; Delphine L Chen
Journal:  J Nucl Med       Date:  2016-09-01       Impact factor: 10.057

3.  Developing PI3K Inhibitors for Respiratory Diseases.

Authors:  E Fagone; M Fruciano; E Gili; G Sambataro; Carlo Vancheri
Journal:  Curr Top Microbiol Immunol       Date:  2022       Impact factor: 4.737

4.  Inhibitory effects of thalidomide on bleomycin-induced pulmonary fibrosis in rats via regulation of thioredoxin reductase and inflammations.

Authors:  Xiaoying Dong; Xin Li; Minghui Li; Ming Chen; Qian Fan; Wei Wei
Journal:  Am J Transl Res       Date:  2017-10-15       Impact factor: 4.060

Review 5.  Rethinking Idiopathic Pulmonary Fibrosis.

Authors:  Justin M Oldham; Carlo Vancheri
Journal:  Clin Chest Med       Date:  2021-06       Impact factor: 4.967

6.  Upregulation of long noncoding RNA AP003419.16 predicts high risk of aging‑associated idiopathic pulmonary fibrosis.

Authors:  Xiaoyan Hao; Yufeng Du; Li Qian; Dan Li; Xuejun Liu
Journal:  Mol Med Rep       Date:  2017-09-25       Impact factor: 2.952

7.  Performance of Radiomics Features in the Quantification of Idiopathic Pulmonary Fibrosis from HRCT.

Authors:  Alessandro Stefano; Mauro Gioè; Giorgio Russo; Stefano Palmucci; Sebastiano Emanuele Torrisi; Samuel Bignardi; Antonio Basile; Albert Comelli; Viviana Benfante; Gianluca Sambataro; Daniele Falsaperla; Alfredo Gaetano Torcitto; Massimo Attanasio; Anthony Yezzi; Carlo Vancheri
Journal:  Diagnostics (Basel)       Date:  2020-05-15

8.  Assessment of survival in patients with idiopathic pulmonary fibrosis using quantitative HRCT indexes.

Authors:  Sebastiano Emanuele Torrisi; Stefano Palmucci; Alessandro Stefano; Giorgio Russo; Alfredo Gaetano Torcitto; Daniele Falsaperla; Mauro Gioè; Mauro Pavone; Ada Vancheri; Gianluca Sambataro; Domenico Sambataro; Letizia Antonella Mauro; Emanuele Grassedonio; Antonio Basile; Carlo Vancheri
Journal:  Multidiscip Respir Med       Date:  2018-12-01

9.  Artesunate ameliorates lung fibrosis via inhibiting the Notch signaling pathway.

Authors:  Yujuan Liu; Guojin Huang; Biwen Mo; Changming Wang
Journal:  Exp Ther Med       Date:  2017-06-08       Impact factor: 2.447

10.  Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases.

Authors:  Sebastiano Emanuele Torrisi; Nicolas Kahn; Julia Wälscher; Nilab Sarmand; Markus Polke; Kehler Lars; Monika Eichinger; Claus Peter Heussel; Stefano Palmucci; Francesca Maria Sambataro; Gianluca Sambataro; Domenico Sambataro; Carlo Vancheri; Michael Kreuter
Journal:  BMC Pulm Med       Date:  2019-11-12       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.